|Dr. Deborah Ann Rathjen B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C.||CEO, MD & Exec. Director||N/A||N/A||60|
|Dr. Jens D. Mikkelsen M.D., Ph.D.||Chief Scientific Officer & Scientific Advisor||294.24k||N/A||N/A|
|Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS||Legal Counsel & Company Sec.||304.74k||N/A||N/A|
|Mr. Steven Lydeamore MBA,CPA||Chief Financial Officer||N/A||N/A||N/A|
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.